ICICIPRULI - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

📊 Investment Analysis: ICICI Prudential Life Insurance (ICICIPRULI)

Investment Rating: 3.3

🔎 Fundamental Overview

ROE (10.3%) and ROCE (11.8%) are average, not outstanding for the insurance space.

P/E: 70.7 vs industry average of 73.9 — slightly better, but still very high, demanding exceptional growth to justify.

PEG Ratio: 4.41 — major red flag. It reflects extremely stretched valuations relative to growth.

EPS: ₹8.73 — modest earnings, not enough to support such a high P/E.

Dividend Yield: 0.14% — negligible. Income generation isn’t a strength here.

Debt-to-Equity: 0.21 — clean balance sheet, offering some financial comfort.

📌 The fundamentals paint a picture of a company in a niche sector with stable cash flows, but currently overpriced.

📉 Price Trends & Technical Signals

Current Price: ₹616 is below both 50-DMA (₹636) and 200-DMA (₹630) — reflects a short-term bearish sentiment.

MACD: -7.19, RSI: 37.6 — hints at a potentially oversold condition, but not yet compelling enough to spark a trend reversal.

Volume consistent, no major divergence — indicates lukewarm interest.

52-week Index: 35.5% — slow annual growth vs competitors.

🎯 Ideal Entry Price Zone: ₹540 – ₹570 This band captures technical support near the 52-week low and cushions valuation risk.

🧭 Holding Strategy / Exit Plan

If you already hold ICICIPRULI, consider the following

✅ Hold Conditions

Holding Period: 1–2 years, with tight review intervals.

Continue holding only if

ROE trends toward 13–15%

PEG drops under 2.0

EPS growth is visible across consecutive quarters

Quarterly PAT stabilizes above ₹350 Cr.

🛑 Exit Signals

Partial Exit: Around ₹670–₹690 if there’s a bounce — aligns with DMA resistance zones.

Full Exit

PEG remains above 4 for 2+ quarters

ROE stagnates below 10%

Price breaches ₹570 with falling volume and worsening MACD

Institutional sentiment weakens (continued FII outflows)

ICICI Prudential is a brand-driven play in life insurance, but right now it's wearing a valuation crown too heavy for its earnings robe. If you’re looking for steadier compounding or better value, want help scouting Kotak Life or SBI Life for comparison? I’d be happy to draw up a strategy board. 🧩📈

Edit in a page